Cargando…

Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies

Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most promising approaches for the treatment of cancers. Large numbers of cancer reactive T lymphocytes can be generated ex vivo from patient blood by genetic modification to express chimeric antigen receptors (CAR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tantalo, Daniela GM, Oliver, Amanda J, von Scheidt, Bianca, Harrison, Aaron J, Mueller, Scott N, Kershaw, Michael H, Slaney, Clare Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154965/
https://www.ncbi.nlm.nih.gov/pubmed/34035114
http://dx.doi.org/10.1136/jitc-2021-002555
_version_ 1783699108869963776
author Tantalo, Daniela GM
Oliver, Amanda J
von Scheidt, Bianca
Harrison, Aaron J
Mueller, Scott N
Kershaw, Michael H
Slaney, Clare Y
author_facet Tantalo, Daniela GM
Oliver, Amanda J
von Scheidt, Bianca
Harrison, Aaron J
Mueller, Scott N
Kershaw, Michael H
Slaney, Clare Y
author_sort Tantalo, Daniela GM
collection PubMed
description Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most promising approaches for the treatment of cancers. Large numbers of cancer reactive T lymphocytes can be generated ex vivo from patient blood by genetic modification to express chimeric antigen receptors (CAR) specific for tumor-associated antigens. CAR T cells can respond strongly against cancer cells, and adoptive transferred CAR T cells can induce dramatic responses against certain types of cancers. The ability of T cells to respond against disease depends on their ability to localize to sites, persist and exert functions, often in an immunosuppressive microenvironment, and these abilities are reflected in their phenotypes. There is currently intense interest in generating CAR T cells possessing the ideal phenotypes to confer optimal antitumor activity. In this article, we review T cell phenotypes for trafficking, persistence and function, and discuss how culture conditions and genetic makeups can be manipulated to achieve the ideal phenotypes for antitumor activities.
format Online
Article
Text
id pubmed-8154965
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81549652021-06-10 Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies Tantalo, Daniela GM Oliver, Amanda J von Scheidt, Bianca Harrison, Aaron J Mueller, Scott N Kershaw, Michael H Slaney, Clare Y J Immunother Cancer Review Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most promising approaches for the treatment of cancers. Large numbers of cancer reactive T lymphocytes can be generated ex vivo from patient blood by genetic modification to express chimeric antigen receptors (CAR) specific for tumor-associated antigens. CAR T cells can respond strongly against cancer cells, and adoptive transferred CAR T cells can induce dramatic responses against certain types of cancers. The ability of T cells to respond against disease depends on their ability to localize to sites, persist and exert functions, often in an immunosuppressive microenvironment, and these abilities are reflected in their phenotypes. There is currently intense interest in generating CAR T cells possessing the ideal phenotypes to confer optimal antitumor activity. In this article, we review T cell phenotypes for trafficking, persistence and function, and discuss how culture conditions and genetic makeups can be manipulated to achieve the ideal phenotypes for antitumor activities. BMJ Publishing Group 2021-05-25 /pmc/articles/PMC8154965/ /pubmed/34035114 http://dx.doi.org/10.1136/jitc-2021-002555 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Tantalo, Daniela GM
Oliver, Amanda J
von Scheidt, Bianca
Harrison, Aaron J
Mueller, Scott N
Kershaw, Michael H
Slaney, Clare Y
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
title Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
title_full Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
title_fullStr Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
title_full_unstemmed Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
title_short Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
title_sort understanding t cell phenotype for the design of effective chimeric antigen receptor t cell therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154965/
https://www.ncbi.nlm.nih.gov/pubmed/34035114
http://dx.doi.org/10.1136/jitc-2021-002555
work_keys_str_mv AT tantalodanielagm understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies
AT oliveramandaj understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies
AT vonscheidtbianca understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies
AT harrisonaaronj understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies
AT muellerscottn understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies
AT kershawmichaelh understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies
AT slaneyclarey understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies